Back to News
Market Impact: 0.25
SeaStar Medical Holding Corporation Announces FDA Determination on QUELIMMUNE Post-Approval Study Requirements on November 3, 2026
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA's Center for Biologics Evaluation and Research determined that SeaStar Medical's QUELIMMUNE Pediatric SAVE Surveillance Registry fulfilled the post-approval study requirements referenced in the announcement. The article text is truncated, so no further details or implications are available.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ICU0.70
More News
- 5 things to watch on Election Day as Democrats push for control of Congress
- Investors poised for possible Democratic gains in Congress as US awaits election results
- Texas race results could kick AI trade while it's already down
- Analysts react to US midterm election results
- Fannie Mae, Freddie Mac rally as Ackman presses for conservatorship exit
- Meta says automation wrongly took down No Kings and a Senate candidate’s page. It’s automating more anyway